Coherus Oncology, Inc. (CHRS)

Over the past six months, several events have impacted Coherus Oncology's stock price. Coherus closed an underwritten public offering of 28.6 million shares of common stock at $1.75 per share on February 17, 2026. On March 9, 2026, Coherus Oncology reported its full-year and fourth-quarter 2025 financial results, with LOQTORZI net revenue more than doubling in 2025. On November 6, 2025, Coherus reported its third-quarter 2025 financial results, with LOQTORZI net revenue increasing by 92% over Q3 2024. On September 5, 2025, Coherus announced it had regained compliance with Nasdaq's minimum bid price requirement. On May 12, 2025, Coherus reported Q1 2025 financial results, with LOQTORZI net product sales of $7.3 million. The company's share price has been highly volatile over the past three months.

Information regarding specific demand seasonality for Coherus Oncology's products and services is not explicitly available. However, the company has reported consistent growth in patient demand for its key oncology product, LOQTORZI. These figures suggest a steady increase in demand rather than explicit seasonal fluctuations.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on researching, developing, and commercializing immunotherapies to treat cancer in the United States. The company operates within the Health Care sector and the Biotechnology industry. Coherus has shifted its focus from biosimilar development to innovative oncology, including the divestiture of its UDENYCA biosimilar franchise in April 2025. Its major products and pipeline candidates include LOQTORZI, Casdozokitug, CHS-114, UDENYCA, YUSIMRY, CIMERLI, CHS-1000, and GSK4381562.

Coherus Oncology, Inc. is headquartered in Redwood City, California, United States. The company's primary commercial focus for its immunotherapies is the United States market. While it previously had a global biosimilar focus, its current strategic emphasis is on the U.S. oncology market.

In the past year, Coherus Oncology has maintained a generally positive or neutral brand reputation. Analyst ratings show a consensus "Buy" for the stock. One assessment from October 2025 categorized Coherus Oncology as "Lower Risk" regarding corporate governance and public policy. No significant negative events or controversies directly impacting Coherus Oncology's brand reputation were found in the past year.

Coherus Oncology, Inc.'s ownership is distributed among institutional, retail, and individual investors. As of March 31, 2025, institutional investors held approximately 69.62 million shares. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., Kohlberg Kravis Roberts & Co. L.P., Geode Capital Management, LLC, Tang Capital Management, LLC and State Street Global Advisors, Inc. Dennis M. Lanfear, the President, CEO, and Chairman, held 1.05% ownership as of April 24, 2025. Vsciences Investments Pte Ltd is also noted as a large individual shareholder.